Compounds > 2-hexyl-4-pentynoic acid
Page last updated: 2024-09-05

2-hexyl-4-pentynoic acid and ER-Negative PR-Negative HER2-Negative Breast Cancer

2-hexyl-4-pentynoic acid has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Cai, Z; Ding, C; Ding, W; Feng, Z; Li, Q; Lim, D; Liu, G; Su, B; Zhang, F1

Other Studies

1 other study(ies) available for 2-hexyl-4-pentynoic acid and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Histone deacetylase inhibitor 2-hexyl-4-pentynoic acid enhances hydroxyurea therapeutic effect in triple-negative breast cancer cells.
    Mutation research. Genetic toxicology and environmental mutagenesis, 2022, Volume: 873

    Topics: Cell Cycle; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; Drug Synergism; Fatty Acids, Unsaturated; Histone Deacetylase Inhibitors; Humans; Hydroxyurea; Triple Negative Breast Neoplasms

2022